BioSpace News Archive

ORIC Pharmaceuticals, Inc. announced that the company will present two poster presentations at the European Society of Medical Oncology Congress 2023 taking place October 20-24, 2023, in Madrid, Spain.

Stoke Therapeutics, Inc. announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary technology reduces immunosuppression and creates a favorable microenvironment that can contribute to immune potentiation.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the Company’s lead product candidate for the treatment of pancreatic cancer.

NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.

ProPhase Labs, Inc., a next generation biotech, genomics, therapeutics and diagnostics company, unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc.

Flamingo Therapeutics announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.

etherna, a leading mRNA/LNP technologies company, announced that Bernard Sagaert has been confirmed-as Chief Executive Officer.

FloBio, a medical diagnostics company, announced today that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test.

VILYA, Inc., a biotechnology company creating a new class of medicines that precisely target disease biology, announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.